Veledimex clinical trials
Also written INXN-1001.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses veledimex is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Alaunos Therapeutics (7) · Castle Creek Biosciences, LLC. (1)
Often tested with
Tested in the same studies.
Ad-RTS-hIL-12 (6) · INXN-3001 (1)
Studies
Open first, then newest update. How each study uses veledimex is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaCompletedPhase 1/2Alaunos TherapeuticsNCT01397708Written as INXN-1001
- Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102CompletedPhase 1Alaunos TherapeuticsNCT03679754Written as veledimex
- A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast CancerTerminatedPhase 1/2Alaunos TherapeuticsNCT02423902Written as Veledimex
- A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedPhase 1Alaunos TherapeuticsNCT03636477Written as veledimex
- Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaTerminatedPhase 2Alaunos TherapeuticsNCT04006119Written as Veledimex
- A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant GliomaCompletedPhase 1Alaunos TherapeuticsNCT02026271Written as veledimex
- A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)TerminatedPhase 1/2Castle Creek Biosciences, LLC.NCT03740724Written as veledimex
- Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV MelanomaCompletedPhase 1Alaunos TherapeuticsNCT00815607Written as INXN-1001
Codes
What other systems call veledimex · ClinicalTrials.gg INT000900
- MeSH (NLM) C000626304veledimexOne source ClinicalTrials.gov
- UNII (FDA) ASU841TV0XVELEDIMEXConfirmed FDA, Wikidata
- Wikidata Q27274109veledimexConfirmed FDA, Wikidata
- NCI Thesaurus C152847VeledimexOne source FDA
- DrugBank DB12170One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626304 | veledimex | One source ClinicalTrials.gov |
| UNII (FDA) | ASU841TV0X | VELEDIMEX | Confirmed FDA, Wikidata |
| Wikidata | Q27274109 | veledimex | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152847 | Veledimex | One source FDA |
| DrugBank | DB12170 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.